Ruxolitinib for the treatment of severe alopecia areata - 14/01/19
Doi : 10.1016/j.jaad.2018.08.040
Lucy Y. Liu, MD a, Brett A. King, MD, PhD b, ⁎ 
b Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
a Yale University School of Medicine, New Haven, Connecticut
∗Reprint requests: to Brett King, MD, PhD, Department of Dermatology, Yale University School of Medicine, PO Box 208059, New Haven, CT 06520Department of DermatologyYale University School of MedicinePO Box 208059New HavenCT06520
| Funding sources: Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. |
|
| Disclosure: Dr King has served on advisory boards for or is a consultant to Aclaris Therapeutics, Inc, Concert Pharmaceuticals, Inc, Eli Lilly and Company, Pfizer, Inc, and Dermavant Sciences Ltd. Dr Liu has no conflicts of interest to disclose. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 2
P. 566-568 - février 2019 Retour au numéro
Article précédent
- Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
- Anne Lynn S. Chang, Duy C. Tran, John G.D. Cannon, Shufeng Li, Mark Jeng, Roma Patel, Lindsay Van der Bokke, Alana Pague, Richard Brotherton, Kerri E. Rieger, Ansuman T. Satpathy, Kathryn E. Yost, Sunil Reddy, Kavita Sarin, A. Dimitrios Colevas
- Tofacitinib for the treatment of alopecia areata in preadolescent children
- Brittany G. Craiglow, Brett A. King
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?